Device Trial Radar · NCT04065490
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Sep 23, 2019
Primary completion
Jan 24, 2023
Study completion Nov 1, 2024
Sponsor
- Lead sponsor
- LumiThera, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 22, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD. Alcon Research, LLC, acquired LumiThera in September 2025.
Conditions
- Dry Age-related Macular Degeneration
Interventions
Valeda Light Delivery SystemDevice
Light delivery system that produces multi-wavelength LED treatment at 590, 660 and 850 nanometers.
Valeda Light Delivery System Sham ModeDevice
Sham light delivery system that emits an approximate 50 times and 100 times reduction in treatment dose for the 590 and 660 nm wavelengths respectively and no emission of the 850 nm wavelength.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Best Corrected Visual Acuity (Letters Read) at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Retina Vitreous Associates Medical Group
Beverly Hills, California
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.